Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01880788 · ClinicalTrials.gov registry record

Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

A clinical trial of Age-related Macular Degeneration and Choroidal Neovascularization, sponsored by Sequenom.

Completed
Registry status
152
Enrollment target
1
Study location

NCT01880788: Completed study of Age-related Macular Degeneration and Choroidal Neovascularization, sponsored by Sequenom.

NCT01880788 is a study of Age-related Macular Degeneration and Choroidal Neovascularization that has completed, run by Sequenom. The registered enrollment target is 152 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01880788, a study of Age-related Macular Degeneration and Choroidal Neovascularization, has completed, sponsored by Sequenom.

COMPLETED
Registry status
152 participants
Enrollment target
1
Study location

Study Summary

The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis. Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

Primary Outcome

The identification of individual genetic markers or a quantitative measure of total genetic burden associated with CNV secondary to CSC vs. CSC vs. CNV secondary to advanced AMD as meaured by the commercially available RetnaGene AMD assay.

Study Locations (1)

New York

  • Vitreous Retina Macula Consultants of New York - New York

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2012-11
Est. Completion 2015-08
Sequenom

26 total trials

What the finished NCT01880788 record still lists

NCT01880788 is an observational study that tracks outcomes without assigning an intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.

NCT01880788 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01880788 about?

NCT01880788 is a clinical study titled "Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD". The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis. Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

What is the current status of trial NCT01880788?

This trial is currently completed. The enrollment target is 152 participants. The study started on 2012-11. Estimated completion is 2015-08.

What conditions does trial NCT01880788 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy.

Who is sponsoring clinical trial NCT01880788?

This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01880788 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01880788's enrollment target sits among peer trials

152 20th of 74 higher than 55 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03328078 · 152 participants · Phase 1

    CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • NCT04458532 · 152 participants · NA

    Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

  • NCT04858334 · 152 participants · Phase 2

    APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  • NCT04993859 · 152 participants

    Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01880788, the US trial registry maintained by the National Library of Medicine. NCT01880788 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.